VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ('Nascent Biotech', 'Nascent', or the 'Company'), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO a 'Speculative Buy' under its tiered rating system, and specified a price target of between $0.39-$1.99.

The full research report may be found at:
https://www.nascentbiotech.com/wp-content/uploads/2021/06/marble-arch-report-6.10.21.pdf

The report concludes, 'We believe that there is a reasonable investment thesis at hand to indicate that the company's market value can rise significantly as its lead development drug, PTB, progresses through its clinical study journey, which has just begun. We rate the stock a Speculative BUY.'

'In its comprehensive report, Marble Arch Research highlights the progress we have made this year as we cross critical milestones on the path toward potential eventual commercialization of our primary platform asset, pritumumab,' commented Sean Carrick, CEO of Nascent Biotech. 'Now that we are well into clinical trials, we look forward to gaining a deeper understanding of how our research can make the greatest possible positive impact for those suffering from the cancers and viral infections we are targeting. And we continue to seek to protect and reward our shareholders for their loyalty, patience and commitment along the way.'

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies (mAbs) for the treatment of incurable cancers such as brain and pancreas, as well as hard-to-treat cancers such as colon and lung. Nascent is also employing its mAbs as part of treatments for dangerous viral infections, such as COVID-19. Collectively, cancers and viral infections afflict and kill tens of millions worldwide each year. Nascent's products are not commercially available. The Company's lead candidate, Pritumumab (PTB), is a fully human mAb that is in an FDA-approved Phase I clinical trial for the treatment of primary and metastatic brain cancer, including glioblastoma and malignant astrocytoma. Development of PTB as a potential treatment for COVID-19 has been initiated.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick
President | CEO | Nascent Biotech, Inc.
772.713.0541 Cell
[email protected]

Public Relations
EDM Media, LLC
https://edm.media

SOURCE: Nascent Biotech, Inc.